IPNP Stock Overview Operates as a biopharmaceutical company worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Ipsen Historical stock prices Current Share Price €107.45 52 Week High €122.00 52 Week Low €102.10 Beta 0.62 1 Month Change 0.14% 3 Month Change n/a 1 Year Change n/a 3 Year Change 35.84% 5 Year Change 35.75% Change since IPO 426.07%
Recent News & Updates Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025
Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis Sep 16
Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases Jul 26
Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024 Jul 25 Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis Jun 13
Ipsen S.A. Approves Dividend, Payable on 3 June 2024 May 29 See more updates Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025
Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis Sep 16
Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases Jul 26
Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024 Jul 25 Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis Jun 13
Ipsen S.A. Approves Dividend, Payable on 3 June 2024 May 29
Ipsen Announces Executive Changes May 03
Dividend of €1.20 announced Apr 20
Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA Feb 15
Full year 2023 earnings released: EPS: €7.79 (vs €7.20 in FY 2022) Feb 10
Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024 Jan 23 Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC Dec 08
Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial Nov 14
Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024 Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024
IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen Aug 22
New minor risk - Profit margin trend Jul 29
First half 2023 earnings released: EPS: €2.36 (vs €4.63 in 1H 2022) Jul 29
Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome Jul 23
Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP Jul 22 Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease Jul 01
Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Jun 15
Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome Jun 14
Ipsen to Present New Data Jun 12
Ipsen S.A. Approves Dividend, Payable on 6 June 2023 Jun 01
Upcoming dividend of €1.20 per share at 1.1% yield May 26
Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023 May 11
Full year 2022 earnings released: EPS: €7.20 (vs €7.64 in FY 2021) Apr 09
Full year 2022 earnings released: EPS: €7.20 (vs €7.82 in FY 2021) Feb 11
Ipsen S.A. Provides Earnings Guidance for the Full Year 2023 Feb 09
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U Jan 27
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI Jan 21
Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million. Jan 09
Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib Dec 09
Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Nov 09
Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023 Oct 27
Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023 Oct 26 Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023
Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022 Oct 22
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer Aug 04
First half 2022 earnings released Jul 29
Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022 Jul 28 Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission Jun 29
Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types May 27
Upcoming dividend of €1.20 per share May 26
Ipsen S.A. Approves Dividend, Payable on 2 June 2022 May 26
Ipsen S.A. Approves Dividend, Payable on 2 June 2022 May 25 Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022
Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer May 04
Ipsen S.A. Provides Sales Guidance for the Year 2022 Apr 27
Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital Feb 16
Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial Feb 15
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 12 Ipsen S.A. Proposes Dividend for the Year 2021
Ipsen Announces the Health Canada Approval of Sohonos as the First Treatment for Fibrodysplasia Ossificans Progressiva Jan 24
Investor sentiment deteriorated over the past week Dec 23
Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer Sep 20
Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-Submit Following Additional Data Analyses Aug 15
First half 2021 earnings released: EPS €3.66 (vs €2.65 in 1H 2020) Jul 31
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021 Jun 08
Ipsen S.A. Confirms U.S. Fda Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (Fop) May 29
Upcoming dividend of €1.00 per share May 24
Ipsen Opts-In to Join Exelixis, Inc With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results May 12
Full year 2020 earnings released: EPS €6.56 (vs €0.66 loss in FY 2019) Apr 16
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo® as First-Line Treatment for Patients Living with Advanced Renal Cell Carcinoma Feb 27
Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline Autogel (lanreotide) Feb 22
Ipsen S.A. Announces New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx® Feb 09
Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living with Renal Cell Carcinoma At ASCO GU 2021 Feb 05
Ipsen Appoints Gwenan White as Executive Vice President Communications and Public Affairs Jan 22
Ipsen Announces New Analyses of Pivotal Phase III Trial Data Highlight Long Duration of Response for Dysport (Abobotulinumtoxina) in Five Therapeutic Indications Jan 15
New 90-day low: €67.15 Jan 06
Ipsen S.A. to Report Fiscal Year 2020 Results on Feb 11, 2021 Dec 23 Shareholder Returns IPNP GB Pharmaceuticals GB Market 7D -1.9% -1.7% -2.6% 1Y n/a -3.5% 2.4%
See full shareholder returns
Return vs Market: Insufficient data to determine how IPNP performed against the UK Market .
Price Volatility Is IPNP's price volatile compared to industry and market? IPNP volatility IPNP Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: IPNP's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine IPNP's volatility change over the past year.
About the Company Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Show more Ipsen S.A. Fundamentals Summary How do Ipsen's earnings and revenue compare to its market cap? IPNP fundamental statistics Market cap €8.88b Earnings (TTM ) €663.90m Revenue (TTM ) €3.44b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IPNP income statement (TTM ) Revenue €3.44b Cost of Revenue €618.00m Gross Profit €2.82b Other Expenses €2.15b Earnings €663.90m
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 13, 2025
Earnings per share (EPS) 8.08 Gross Margin 82.01% Net Profit Margin 19.33% Debt/Equity Ratio 9.6%
How did IPNP perform over the long term?
See historical performance and comparison Dividends
1.1% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 16:38 End of Day Share Price 2024/12/19 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ipsen S.A. is covered by 35 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Richard Silver Barclays Charles Pitman-King Barclays Hae Won Na Berenberg
Show 32 more analysts 
